Effect of AF, olaparib and aurola treatment on immune-related

From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer, Journal of Ovarian Research

ASCO GU 2022: PROpel: Phase III Trial of Olaparib and Abiraterone Versus Placebo and Abiraterone as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Jinthe VAN LOENHOUT, PhD Student

Combination of microtubule targeting agents with other antineoplastics for cancer treatment - ScienceDirect

From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer, Journal of Ovarian Research

Effect of AF, olaparib and aurola treatment on immune-related

Challenges and Opportunities for Childhood Cancer Drug Development

Laurie FREIRE BOULLOSA, PhD Student

The effect of different dose olaparib in ovarian cancer cell lines. (A)

The intracellular gold concentration levels caused by the

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer

Jinthe VAN LOENHOUT, PhD Student

Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review - ScienceDirect